B7-2 Recombinant Protein Cat. No.: 96-972

Availability: In stock

$0.00

 Price Options

$0.00
psi-iconSpecifications
SPECIES:Mouse
SOURCE SPECIES:HEK293 cells
SEQUENCE:Val 24 - Glu 245
FUSION TAG:Fc Tag
TESTED APPLICATIONS:ELISA, WB
APPLICATIONS:This recombinant protein can be used for E, WB. For research use only.
BIOLOGICAL ACTIVITY: Measured by its binding ability in a functional ELISA. Immobilized Mouse B7-2, Fc Tag at 5 ug/mL (100 ul/well),can bind Mouse CTLA-4, His Tag with a linear range of 0.8-12.5 ng/mL (QC tested).
psi-iconProperties
PURITY:>95% as determined by SDS-PAGE.

Endotoxin level is less than 1.0 EU per ug by the LAL method.
PREDICTED MOLECULAR WEIGHT:52 kDa
PHYSICAL STATE:Lyophilized
BUFFER:Tris with Glycine, Arginine and NaCl, pH7.5
STORAGE CONDITIONS:Lyophilized Protein should be stored at -20˚C or lower for long term storage. Upon reconstitution, working aliquots should be stored at -20˚C or -70˚C. Avoid repeated freeze-thaw cycles.
psi-iconAdditional Info
ALTERNATE NAMES:CD86,B7-2,B70,CD28LG2,LAB72,MGC34413
ACCESSION NO.:NP_062261.3
OFFICIAL SYMBOL:B7-2
GENE ID:12524
psi-iconBackground and References
BACKGROUND:Cluster of Differentiation 86 (CD86) is also known as B-lymphocyte activation antigen B7-2, is a type I membrane protein that is a member of the immunoglobulin superfamily, and is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B72 is expressed at low levels on monocytes and can be upregulated through interferon γ. CD86 is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD86 works in tandem with CD80 to prime T cells. Recent study has revealed that B7-2 promotes the generation of a mature APC repertoire and promotes APC function and survival. Furthermore, the B7 proteins are also involved in innate immune responses by activating NF-kappaB-signaling pathway in macrophages. CD86 thus is regarded as a promising candidate for immune therapy. CD86+ macrophages in Hodgkin lymphoma patients are an independent marker for potential nonresponse to firstline-therapy.
REFERENCES:1) Chen C, et al., 1994, J. Immunol. 152 (10): 4929–36.
2) Yadav, D. et al., 2007, J. Immunol. 178: 6236-6241.
3) Steidl C, et al., 2010, N. Engl. J. Med. 362 (10): 875–85.

FOR RESEARCH USE ONLY.

For additional information, visit ProSci's Terms & Conditions Page.